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Introduction 
Both type 1 (subtype 1) and type 2 PRRSV are 
currently circulating in Denmark. In some double 
infected herds, the pigs are simultaneously 
vaccinated with PRRS modified live vaccines (MLV) 
against type 1 and type 2. After vaccination with a 
single PRRS ML vaccine, viraemia can be measured 
for five to seven days (Nielsen et al., 1997). There is, 
however, a lack of data on the impact on vaccine 
efficacy and viral dynamics following simultaneous 
administration of PRRSV MLVs against both type 1 
and type 2 PRRSV. 
The objective of this experimental study was to 
compare the level of viraemia and clinical responses 
of single vaccinated pigs with responses of double 
vaccinated pigs. Furthermore, the efficacy of the two 
vaccination strategies was assessed following 
challenge with homologous and heterologous virus 
strains.   
 
Materials and methods 
Sixty-six, four-week-old PRRSV-negative pigs were 
included in the study. The pigs were purchased from a 
specific pathogen-free herd and verified free of a 
range of pathogens including PRRSV by serology. 
The pigs were housed at the experimental animal 
facilities at the National Veterinary Institute under 
appropriate biosecurity conditions. On arrival (week 0), 
the pigs were randomly distributed into four groups 
(Table 1). Each group was housed in a separate room. 
One week after arrival (week 1), the pigs in groups 
1-3 were vaccinated according to the schedule listed 
in Table 1. Nine weeks after vaccination, all pigs were 
moved to new groups according to the challenge 
strain. The pigs were then challenged with PRRSV 
type 1 (strain 18794), PRRSV type 2 (strain 19407b) 
or PRRSV atypical strain (strain BOR59) by the 
intranasal route according to Table 1.  
Blood samples were collected daily from all pigs 
during the first week after vaccination and challenge. 
In the remaining periods, samples were taken once a 
week from all pigs. 
The level of PRRS virus was quantified by real-time 
reverse transcriptase Polymerase Chain Reaction 
(RT-PCR). Initially, samples from each group were 
tested in pools of nine and subsequently analysed 
individually if the pool tested positive.  
 
Group No. 
pigs 
PRRSV 
vaccination 
PRRSV  
challenge 
VAC- 
T1 
18 Porcilis® 
PRRS VET 
6 pigs type 1 
6 pigs type 2 
6 pigs atypical 
VAC- 
T2 
18 Ingelvac® 
PRRS VET 
6 pigs type 1 
6 pigs type 2 
6 pigs atypical 
Vac- 
T1T2 
18 Porcilis® 
PRRS VET 
+ 
Ingelvac® 
PRRS VET 
6 pigs type 1 
6 pigs type 2 
6 pigs atypical 
Control 12 No 
vaccination 
4 pigs type 1 
4 pigs type 2 
4 pigs atypical 
Table 1. Number of pigs in each of the four groups, 
PRRS vaccination and PRRSV challenge. 
 
Results and discussion  
To date, only pooled samples have been analysed. 
There seemed to be a comparable duration of 
viraemia after vaccination with a single PRRSV 
vaccine and after simultaneous vaccination with the 
two PRRSV vaccines. Similarly, the duration of 
viraemia in pigs vaccinated with the type 2 vaccine 
was similar to that in pigs vaccinated with the type 1 
vaccine.  
No clinical symptoms were observed after challenge. 
In pigs vaccinated against PRRSV type 2, no viraemia 
was measured after challenge with type 2 virus. In all 
other groups, viraemia was measured at various 
times after challenge. In general, there was limited 
cross-protection against challenge with heterologous 
virus, and none of the vaccines protected against 
challenge with the atypical BOR59 strain. Further 
results will be presented at the meeting.   
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